Cellnovo Limited announced the appointments of three executives to the senior management team. Bart Bergstein has been appointed as Chief Financial Officer, Steve Bubrick as Vice President Global Marketing and Business Development, and Didier Moire as Area Director of newly created Cellnovo France. Bart Bergstein has a 24 year track record in the financial industry including 14 years in Venture Capital. After joining the private equity arm of ABN AMRO in 1997, Bart established the AMRO Life Sciences Team that later spun out as Forbion Capital Partners. Steve Bubrick has more than 20 years of experience in the diabetes industry. He joins Cellnovo from Asante Solutions where he held the position of Vice President Commercial Operations. Prior to Asante, Steve held senior commercial positions at Insulet, Abbott, Therasense and Lifescan where he was involved in bringing disruptive monitoring and insulin delivery products to markets worldwide. Steve will also be in charge of laying the foundations of Cellnovo's business in North America, starting with overseeing its regulatory filing process.

Recognizing the importance of the diabetes market in France, Cellnovo has created a subsidiary in the country with an office in Paris, where Didier Moire will be based and responsible for sales in France, Belgium and Luxembourg. Didier has more than 25 years' experience in Medical Technology and Diagnostics. He was previously Managing Director France/Benelux for Immucor and also held senior positions in Chiron and Novartis.